Naing Htike, MD
Nephrology · Memphis, TNNPI 1891020871
Payments from drug & device makers
Across 100 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$521
- Bayer$416
- Travere Therapeutics, Inc.$296
- Vifor Pharma, Inc.$219
- Lilly USA, LLC$165
- Ardelyx, Inc.$142
- plus $910 from 16 others
What the payments were for
- Food & beverage$2,54395%
- Education$1265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $521 |
| Bayer | 21 | $416 |
| Travere Therapeutics, Inc. | 15 | $296 |
| Vifor Pharma, Inc. | 11 | $219 |
| Lilly USA, LLC | 6 | $165 |
| Ardelyx, Inc. | 5 | $142 |
| AstraZeneca | 3 | $138 |
| Daxor Corporation | 1 | $111 |
| Amgen | 1 | $108 |
| Veloxis Pharmaceuticals, Inc. | 1 | $96 |
| Novartis | 3 | $89 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| OPKO Pharmaceuticals, LLC | 3 | $62 |
| Novo Nordisk | 2 | $48 |
| Boehringer Ingelheim | 2 | $34 |
| GSK | 2 | $27 |
| Akebia Therapeutics Inc | 1 | $27 |
| Cormedix Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,669 in reported general payments places this provider in the 65th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 189 | $414,932 |
| FarxigaDapagliflozin Propanediol | 195 | $182,489 |
| JardianceEmpagliflozin | 104 | $92,675 |
| OzempicSemaglutide | 45 | $43,211 |
| RayaldeeCalcifediol | 34 | $39,104 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $28,027 |
| Sevelamer Carbonate | 126 | $22,592 |
| MounjaroTirzepatide | 17 | $20,211 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $19,726 |
| Potassium Chloride | 116 | $2,654 |
| Losartan Potassium | 318 | $2,213 |
| Bumetanide | 64 | $1,877 |
| Hydralazine Hcl | 121 | $1,527 |
| Olmesartan Medoxomil | 130 | $1,435 |
| Rosuvastatin Calcium | 106 | $1,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $19 | $414,932189 claims |
| AstraZenecaFarxiga, Lokelma | $138 | $202,216222 claims |
| Boehringer IngelheimJardiance | $34 | $92,675104 claims |
| Novo NordiskOzempic | $48 | $43,21145 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $62 | $39,10434 claims |
| Lilly USA, LLCMounjaro | $165 | $20,21117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Memphis
- Wael HusseinMemphis$912K
- Lekha GeorgeMemphis$164K
- Omar DavisMemphis$118K
- Omar HamzeMemphis$90K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Sanjeev MittalMemphis$13K
- Miklos MolnarMemphis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.